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Self-aggregation of transforming growth factor b (TGF-b)1-induced antiapoptotic factor (TIAF1) is known in the nondemented
human hippocampus, and the aggregating process may lead to generation of amyloid b (Ab) for causing neurodegeneration.
Here, we determined that overexpressed TIAF1 exhibits as aggregates together with Smad4 and Ab in the cancer stroma and
peritumor capsules of solid tumors. Also, TIAF1/Ab aggregates are shown on the interface between brain neural cells and the
metastatic cancer cell mass. TIAF1 is upregulated in developing tumors, but may disappear in established metastatic cancer
cells. Growing neuroblastoma cells on the extracellular matrices from other cancer cell types induced production of aggregated
TIAF1 and Ab. In vitro induction of TIAF1 self-association upregulated the expression of tumor suppressors Smad4 and WW
domain-containing oxidoreductase (WOX1 or WWOX), and WOX1 in turn increased the TIAF1 expression. TIAF1/Smad4
interaction further enhanced Ab formation. TIAF1 is known to suppress SMAD-regulated promoter activation. Intriguingly,
without p53, self-aggregating TIAF1 spontaneously activated the SMAD-regulated promoter. TIAF1 was essential for p53-,
WOX1- and dominant-negative JNK1-induced cell death. TIAF1, p53 and WOX1 acted synergistically in suppressing anchorage-
independentgrowth,blockingcellmigrationandcausingapoptosis.Together,TIAF1showsanaggregation-dependentcontrolof
tumor progression and metastasis, and regulation of cell death.
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Transforming growth factor b (TGF-b) family proteins partici-
pate in a variety of biological events and diseases, including
cell proliferation, immune response, apoptosis, oncogenesis
and many physiological events.
1,2 TGF-b has dual roles in
cancer initiation and progression.
3,4 TGF-b inhibits epithelial
cell growth, and induces epithelial to mesenchymal transition
(EMT). Cancerous cells are refractory to TGF-b-mediated
growth suppression, and produce autocrine TGF-b for
their growth and metastasis. The mechanism of this regard
is largely unknown.
TGF-b1-induced antiapoptotic factor (TIAF1) is a 12-kDa
TGF-b1-induced antiapoptotic factor, which protects murine
L929 ﬁbroblasts from apoptosis by tumor necrosis factor
(TNF) and overexpressed TNF receptor adaptor proteins
in the presence of actinomycin D, an inhibitor of DNA
transcription.
5,6 Transiently overexpressed TIAF1 supports
ﬁbroblast growth, which is similar to the effect of TGF-b1.
6
Also, like TGF-b1, ectopic TIAF1 suppresses cell growth
and induces apoptosis of monocytic U937 and many non-
ﬁbroblast cells.
6 TIAF1 increases the expression of p53 and
Cip1/p21 and suppresses ERK phosphorylation in U937 cells,
therebyinhibitingcell growthandinducingapoptosis.
6Ectopic
TIAF1 upregulates the expression of tumor suppressor p53,
and both proteins mediate cell death in either a cooperative or
an antagonistic manner.
7 Suppression of TIAF1 expression
by small interfering RNA (siRNA) prevents UV irradiation-
mediated p53 phosphorylation and nuclear translocation.
Expression of TIAF1 is signiﬁcantly increased in activated
helper T lymphocytes (TH2) in patients with chronic kidney
and liver allograft rejection.
8 Regulatory T cells (Treg) have a
signiﬁcantly increased expression of TIAF1.
9 Whether TIAF1
controls the differentiation and activation-induced death of
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www.nature.com/cddisTreg and TH2 cells is unknown. TIAF1 is also associated with
Hirschsprung’s disease, a congenital complex disorder
of intestinal innervation.
10
TIAF1 physically interacts with Smad4, and blocks SMAD-
dependent promoter activation when overexpressed.
11
Knockdown of TIAF1 by siRNA induces spontaneous accu-
mulation of Smad proteins in the nucleus and activation of the
promotergovernedbytheSMADcomplex.
11Notably,TGF-b1
and environmental stress (e.g. alterations in pericellular
environment) cause TIAF1 self-aggregation in a type II
TGF-b receptor (TbRII)-independent manner in cells. Hippo-
campal TIAF1 aggregation is shown at ages 40–70, which
occurs before the generation of amyloid b (Ab) plaques in
Alzheimer’s disease at 75–90-years.
11 Here, we examined
TIAF1 expression and aggregate formation in cancer cells
and tissues, and determined the functional relationship
between TIAF1 and tumor suppressors WW domain-contain-
ing oxidoreductase (designated WWOX, FOR or WOX1)
12–14
and Smad4. TIAF1 control of SMAD-regulated promoter
activation was examined.
Results
TIAF1 expression is upregulated in non-metastatic
prostate cancer but is downregulated in breast cancer.
A synthetic TIAF1 peptide R48-2, which was originally used
for the antibody production,
5,11 blocked the immunoreactivity
in antibody staining, as determined in human melanoma
(Supplementary Figure S1a), neuroﬁbromatosis NF1 tumor
(Supplementary Figure S1b), meningioma (Supplementary
Figure S1c) and breast cancer (Figure 1a and Supple-
mentary Figures S2g–i) and other tissue sections. The R48-2
peptide also blocked the immunoreactivity of a commercial
antibody TIAF1(Abcam, Cambridge, MA, USA) (Supple-
mentary Figure S1a). We generated another TIAF1(R48-1)
antibody using a different peptide sequence. The
TIAF1(R48-2) peptide failed to inhibit the immunoreactivity
of TIAF1(R48-1) antibody (Supplementary Figure S1c).
TIAF1 expression is shown in normal human mammary
gland cells, as determined by immunohistochemistry (IHC)
(Figure 1a and Supplementary Figure S2). In breast adeno-
carcinoma, the levels of TIAF1 are signiﬁcantly reduced
(Figure 1a and Supplementary Figure S2). In negative
controls, the R48-2 peptide blocked the immunoreactivity of
TIAF1 antibody (Figure 1a).
In prostate tissue microarray slides, TIAF1 levels are
signiﬁcantly increased in prostate cancer, compared with
normal controls, as determined using both TIAF1(R48-2) and
the commercial antibodies for ﬂuorescence microscopy
(Figure 1b; 75 samples for control and cancer groups and
damaged samples excluded). Both antibodies recognized
essentially the sameTIAF1 antigen, asboth images appear to
colocalize (Supplementary Figure S1a). Similar results were
observed using the TIAF1(R48-2) antibody in IHC (data not
shown). We further conﬁrmed these ﬁndings by using normal
prostateand prostate cancersections in immunoﬂuorescence
microscopy and IHC (Figure 1c, Supplementary Figures S3a
and S4). Compared with age-matched normal controls, there
were signiﬁcant increases (50–120%) in the expression of
TIAF1inprostatecancertissues(SupplementaryFiguresS3a
and S4). In negative controls, R48-2 peptide blocked the
immunoreactivity (Supplementary Figure S4).
TIAF1 aggregates in cancer cells. TIAF1 physically inter-
acts with Smad4, and knockdown of TIAF1 expression
induces spontaneous accumulation of Smad proteins in the
nuclei.
11 By immunoﬂuorescence microscopy, TIAF1 co-
localized with Smad4 in the cytosol and prostatic concretions
in the lumens of glandular ducts (Supplementary Figures S3b
and S3c). Upregulation of TIAF1 and Smad4 is shown in the
prostate cancer tissues (Figure 1c, Supplementary Figures
S3 and S4). Both TIAF1 and Smad4 proteins are colocalized
and appear as aggregates (Supplementary Figures S3b and
S3c). Notably, expression of both TIAF1 and Smad4 are
signiﬁcantly downregulated in metastatic prostate cancer
cells (Figure 1c and Supplementary Figure S5). Similarly,
expression of TIAF1 and Smad4 proteins is signiﬁcantly
increased (Po0.05) in colon cancer cells, as compared with
controls (Supplementary Figure S6). IHC staining of prostate
with the TIAF1(R48-2) antibody showed a poorly differen-
tiated tumor growing in a diffused fashion (Figure 1d). The
tumor inﬁltrates the prostate as cell clusters, without
glandular formation and containing TIAF1 protein aggregates
(Figure 1d).
Next, hairless mice were exposed to UVB irradiation to
generate skin squamous cell carcinoma (SCC).
15 TIAF1 is
overexpressed in the sebaceous gland of the normal skin
(Figure 1e). UVB rapidly increased the expression of TIAF1 in
the epidermis in 12h, followed by reduction. However, in the
dermal area, TIAF1 levels were increased from 24h to
1month after UVB exposure. The developed SCC tumors
had reduced expression of TIAF1 (Figure 1e).
TIAF1 aggregation in the metastatic cancer cells in the
brain. TIAF1 aggregates are present in the hippocampi of
both non-demented humans and patients with Alzheimer’s
disease.
11 Co-expression of TIAF1 and Ab aggregates was
found in the metastatic cancer in the brain (Figures 2a and b).
Conceivably, when metastatic small-cell lung cancer cells
relocated to the brain, TIAF1 aggregates were deposited in
the interface between cancer and brain cells or within
the tumors (Figures 2a and b, Supplementary Figures S7
and S8). Fluoro-Jade C stain
11 demonstrated the presence
of degenerating neurons (Figures 2a and b, Supplementary
Figures S7 and S8). In negative controls, R48-2 peptide
blocked the immunostain (Figures 2a and b, Supplementary
Figures S7 and S8). Similarly, co-expression of the aggre-
gates for TIAF1 and Ab was shown for the metastatic lung
cancer, nasopharyngeal carcinoma (NPC) and colon cancer
in the brain (Figure 2b, Supplementary Figures S7 and S8).
Despite the presence of Ab, no apparent apoptosis was
observed in the cancer cells.
ComparedwithTIAF1,WOX1expression isrelatively lowin
neuroﬁbromatosis NF1 (Figures 2c and d). TIAF1 is over-
expressed in the peritumor area (Figure 2d). Alteration of
environmental cues induces TIAF1 expression and aggrega-
tion.
11 Presence of ﬁbrous aggregation of TIAF1 is shown in
the peritumor coat of NF1 (Figure 2e), prostate cancer
(Supplementary Figure S9), many solid tumors and
hippocampi of patients with Alzheimer’s disease (data not
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Cell Death and Diseaseshown). Again, R48-2 peptide blocked the immunoreactivity
(Figure 2f).
When metastatic 13-06-MG glioma cells were subcuta-
neously inoculated in both ﬂanks of nude mice, the cells
were metastatic to the lung. Presence of high levels of TIAF1
expression is shown in the growing tumor, compared with the
normal lungs of nude mice (Figure 2g).
Extracellular matrix (ECM) proteins induce the expres-
sion and aggregation of TIAF1 and Ab, and ectopic
WOX1 upregulates TIAF1 expression. To simulate the
encounter of metastatic cancer cells with brain cells,
neuroblastoma SK-N-SH cells were cultured on the ECM of
prostate DU145 cells for 48h.
11,16 SK-N-SH cells were
shown to have overexpressed aggregates of TIAF1 and Ab,
as determined by ﬂuorescent immunostaining (Figures 3a
and b). However, when the endogenous TIAF1 level was low,
Ab expression was also low (Figure 3b). In negative controls,
cells were seeded onto serum protein-coated matrix where
no TIAF1 and Ab production was observed (data not shown).
Figure 1 TIAF1 expression in breast, prostate and skin cancers. (a) IHC staining of normal and breast cancer tissue sections revealed a signiﬁcant reduction of TIAF1 in
thecancertissues,usingTIAF1(R48-2)antibody(Student’st-test).Innegativecontrol,R48-2peptideblockedtheimmunoreactivityoftheantibody.Also,seeadditionaldatain
Supplementary Figure S2. (b) TIAF1 protein expression is signiﬁcantly increased in prostate cancer, compared with normal controls, as determined using both the TIAF1
(R48-2) antibody (left panel) and a commercial TIAF1 antibody (right panel) for immunoﬂuorescence microscopy in prostate tissue microarray slides from NCI (Student’s
t-test).
11,17,35,39 Also, see data in Supplementary Figures S3, S4 and S5. (c) By immunoﬂuorescence microscopy, signiﬁcant increases (50–120%) in the TIAF1 protein
expression were shown in prostate cancer tissues (three cases), as compared with samples from age-matched normal controls, prostatic hyperplasia and metastatic prostate
cancer.Innegativecontrols(Negative),non-immuneserumwasusedforstaining.Scalebar,100mm;  100magniﬁcation.MergedimagesofTIAF1(green)andSmad4(red)
are shown. Also, see detailed pictures in the Supplementary Figure S5. (d) A poorly differentiated tumor grew in the prostate as cell clusters with no glandular formation but
contained TIAF1 protein aggregates. Graphs are sequentially enlarged from each red box (from top left, bottom left to right). (e) UVB irradiation induced formation of SCC in
hairless mice. TIAF1 protein expression is abundant in the sebaceous gland of the normal skin. The developed SCC tumors have low levels of TIAF1. Scale bar¼50mm
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Cell Death and DiseaseAlso, petri dishes were coated with various amounts of matrix
proteins from DU145, followed by seeding with SK-N-SH
cells. Two days later, SK-N-SH cells were harvested
and shown to have increased levels of polymerized Ab
(Figure 3c). The smallest unit of Ab is B4kDa. Similar results
were observed by culturing SK-N-SH cells on the matrix of
many other types of cancer cells such as breast MCF7 and
lung NCI-H1299 cells (data not shown).
We simulated the potential effects of brain metastatic
cancer cells on neural cells by co-culturing. SK-N-SH cells
wereco-culturedwithCOS7ﬁbroblasts,followed bydetermin-
ing the expression of TIAF1. SK-N-SH cells were transiently
overexpressed with enhanced cyan ﬂuorescence protein
(ECFP), and COS7 cells with EYFP. When both cells were
co-cultured for 24h, TIAF1 was not induced (Figures 3d
and e). However, transiently overexpressed EYFP-WOX1
dramatically induced TIAF1 expression in COS7 cells
(Figures 3d and e).
Aggregating TIAF1 induces spontaneous activation of
SMAD-responsive promoter in p53-deﬁcient NCI-H1299
cells. TIAF1 physically interacts with Smad4 and sup-
presses the SMAD-driven promoter activation.
11 When
COS7 cells were transiently overexpressed with Smad4, in
the presence of a SMAD promoter plasmid (containing green
ﬂuorescence protein (GFP) as reporter), the promoter
became activated (Figure 4a). Transiently overexpressed
TIAF1 blocked Smad4-induced promoter activation
(Figure 4a). When p53-deﬁcient NCI-H1299 cells were
transfected with TIAF1 or WOX1, in the presence of
the SMAD promoter plasmid, spontaneous activation of the
promoter occurred (Figure 4b). TIAF1 was tagged with
Figure 2 TIAF1 aggregation in the interface between metastatic cancer cells and the brain tissues. (a) Presence of aggregated TIAF1 in the dead neurons located in the
interface between the brain tissue and the metastatic small-cell lung cancer. Degenerating neurons were stained with Fluoro-Jade C (red). Nuclei were stained with DAPI.
Scalebar,20mm;  400magniﬁcation.AmergedimageisofTIAF1(green),Fluoro-JadeC(red)andDAPI(blue).TheblockingR48-2peptidewasusedinnegativecontrols.
Also, see Supplementary Figures S7 and S8. (b) TIAF1/Ab aggregatesare shown in a metastatic lung adenocarcinoma in the brain. Scale bar, 20mm;  400 magniﬁcation.
A mergedimageisof TIAF1 (green),Ab (red) andDAPI (blue).TheblockingR48-2peptidewas usedin negativecontrols.(c andd)In IHC staining,expressionof WOX1 and
TIAF1 is shown in neuroﬁbromatosis NF1. TIAF1 is overexpressed in the peritumor area, but is less expressed in the tumor itself. Scale bar, 100mm. (e) Fibrous protein
aggregates are shown in the peritumor coats of neuroﬁbromas. TIAF1 is present in the ﬁbrous aggregates ( 400 magniﬁcation). (f) R48-2 peptide was used to block the
immunoreactivity in the negative control staining. (g) Metastatic 13-06-MG glioma cells were subcutaneously inoculated and shown to metastasize to the lung of a nude
mouse. The growing tumor in the lung showed a high level expression of TIAF1 as compared with the normal lung of a nude mouse. Scale bar, 200mm;  400 magniﬁcation
(IHC). A representative data set is shown from three repeats
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However, when TIAF1 was tagged with monomeric DsRed,
no spontaneous activation of the SMAD-governed promoter
was observed (Figure 4b). TIAF1, tagged with DsRed,
EGFP, ECFP or EYFP, tended to aggregate, whereas
monomeric DsRed-TIAF1 (TIAF1dm) remained mainly as
monomer.
TIAF1 self-association induces expression of Smad4
and WOX1. In agreement with our previous observations,
11
ectopic expression of TIAF1 tagged with ECFP or EYFP
(ECFP-TIAF1 or EYFP-TIAF1) in breast MCF7 cells resulted
in an increased self-binding, as determined by FRET (Fo ¨rster
resonance energy transfer) analysis (Figure 5a).
11,17 The
TIAF1 self-binding led to an increased expression of Smad4,
and both Smad4 and TIAF1 colocalized in the cytoplasm and
cellular protrusion (Supplementary Figure S10). TGF-b1
marginally reduced the effects (Figure 5a).
By non-reducing SDS-PAGE and western blotting, transi-
ently overexpressed EGFP-TIAF1 induced the expression of
Smad4 and WOX1 in MCF7 (Figure 5b) and other types of
cancer cells (data not shown). TIAF1 self-polymerized, as the
molecular sizes are 495kDa (TIAF1 monomer, 12kDa;
EGFP-TIAF1, 44kDa). Prima-1, an activator of p53,
18 further
increased TIAF1 polymerization by more than 200kDa
(Figure 5b). The induced Smad4 exhibited as a monomer
(Figure 5b). Under the inﬂuence of ectopic TIAF1, WOX1
polymerized from a monomer Z46kDa (Figure 5b). In
parallel, ectopic EGFP-TIAF1 formed cytoplasmic punctate
aggregates, with concurrent expression of WOX1 (Figure 5c).
Figure 3 ECM proteins induce the expression and aggregation of TIAF1 and Ab, and ectopic WOX1 upregulates TIAF1 expression. (a) Neuroblastoma SK-N-SH cells
were cultured on the ECM of prostate DU145 cancer cells. Extracellular protein matrix from DU145 cells was prepared as described.
11,16 Note that TIAF1 and Ab protein
aggregates are colocalized or exist alone. In negative controls, R48-2 blocking peptide was used in the immunostaining (merge of DAPI and TIAF1 images).
Two representative data are shown from three experiments ( 400 magniﬁcation; 50 cells examined per experiment). (b) Data are tabulated for endogenous TIAF1
expression at low and high levels, relative to the expression of Ab (mean±S.D.; Student’s t-test; n¼3; all data versus low expression TIAF1 controls).
11,17,35,39 In negative
controls,cellswere seededonto serumproteins-coated matrix,whichdid notinduce TIAF1andAb production.Fluorescenceintensitywas o25.(c)Petridisheswere coated
with various amounts of matrix proteins from DU145, followed by seeding with SK-N-SH cells. Two days later, Western blotting for Ab expression was performed. Ab is
polymerizedtovarioussizes.ThemonomericAbisB4kDa.Coatedproteins:lane1,0mg;lane2,1mg;lane3,2mg;andlane4,4mg.a-tubulinisregardedasprotein-loading
control.(dande)SK-N-SHcellswereexpressedwithECFP,andCOS7cellswithEYFPorEYFP-WOX1.Co-cultureofECFP-SK-N-SHandEYFP-COS7cellsdidnotresultin
inductionofTIAF1expression.However,ECFP-WOX1alonewassufﬁcienttoinduceTIAF1expressioninCOS7cells(mean±S.D.;Student’st-test;n¼3;50cellsexamined
per experiment)
11,17,35,39
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Cell Death and DiseaseBoth EGFP and dominant-negative EGFP-TIAF1
11 failed to
induce WOX1 expression (Figure 5c). When TIAF1 was
tagged with monomeric DsRed, no aggregate formation was
observed (data not shown).
Endogenous TIAF1 aggregate formation requires
culturing two distinct cell types on non-self ECM. By
co-culturing both COS7 ﬁbroblasts and neuroblastoma SK-
N-SH cells on the ECM of prostate DU145 cells for 48h,
endogenous TIAF1 became punctate aggregates in the
cytoplasm of both cells, as determined by using speciﬁc
TIAF1(R48-2) antibody (top two rows; Figure 5d). WOX1
expression was also increased (Figure 5d). No TIAF1
aggregate formation was observed by culturing COS7 cells
alone on the ECM (Figure 5d). Again, the R48-2 blocking
peptide abolished the immunoﬂuorescence (Figure 5d). The
observations suggest that when two distinct types of cells
encounter each other, endogenous TIAF1 aggregation may
occur.
TIAF1-/Smad4-binding induces generation of amyloid
precursor protein (APP) and Ab. p53-deﬁcient NCI-H1299
cells were transiently overexpressed with ECFP-Smad4 and
EYFP-TIAF1. The cells were treated with TGF-b1 for 24h,
which resulted in an increased generation of APP and Ab
(Figure 5e). By FRET analysis, TGF-b1 increased the
binding of Smad4 and TIAF1 (Figure 5e). Similar results
were also obtained using p53-positive MCF7, COS7 and
L929 cells (data not shown).
TIAF1 is required for WOX1-, p53- and dominant-
negative JNK1 (dnJNK1)-mediated apoptosis. We exam-
ined whether TIAF1 participates in WOX1- and p53-mediated
apoptosis. TGF-b-sensitive mink lung epithelial Mv1Lu cells
were transfected with expression constructs of WOX1 and/or
siRNA-targeting TIAF1 (TIAF1si)
5,7 by electroporation,
followed by culturing for 48h. In controls, a ‘scrambled
RNA’ plasmid was used in transfection. When endogenous
TIAF1 was knocked down by siRNA, WOX1-induced growth
inhibition of Mv1Lu cells was blocked (Figure 6a).
Similarly, L929 cells were transfected with the expression
plasmids of WOX1 and/or TIAF1si by electroporation, and
were then grown in soft agarose for 3 weeks. Presence of live
colonies was measured using MTS proliferation assay.
7
WOX1 signiﬁcantly inhibited the anchorage-independent
growth of L929 cells (Po0.001; n¼3; Student’s t-test), when
compared with control cells transfected with the ‘scrambled
RNA’ plasmid (Figure 6b). However, WOX1 did not inhibit the
growth of TIAF1si-expressing cells (P40.05; n¼3; Student’s
t-test), suggesting that WOX1-induced growth suppression is
TIAF1-dependent.
WOX1 and TIAF1 worked synergistically to induce cell
death. Transient expression of low levels of WOX1 or TIAF1
did not cause L929 cell death (o10%) (Figure 6c). When in
combination, both WOX1 and TIAF1 signiﬁcantly caused cell
death (B40%) (Figure 6c). Dominant-negative WOX1
(dnWOX1) alone did not induce cell death, in the absence or
presence of TIAF1 (Figure 6c). dnWOX1 is known to block
the apoptotic functions of p53 and WOX1.
12–14,17 Alteration of
Tyr33 and Tyr61 in WOX1 abolishes its apoptotic function,
and noenhancement of apoptosis occurred in the presence of
TIAF1 (Figure 6c). Tyr61 is a conserved phosphorylation site
and its phosphorylation status has been conﬁrmed by speciﬁc
antibody (Chang et al., unpublished).
We determined whether TIAF1 or WOX1 knockdown
causes resistance to p53-dependent apoptosis. L929 cells,
which were stably transfected with a scramble, TIAF1si or
WOX1si construct, were electroporated with an empty vector,
a p53 or a dnJNK1 expression plasmid. In agreement with our
previous studies,
12,19,20 both transiently overexpressed p53
Figure4 TIAF1self-aggregationisessentialforcausingspontaneousactivationofaSMAD-responsivepromoterinp53-deﬁcientcells.(a)COS7cellsweretransfectedby
liposome with plasmids for expressing ECFP, ECFP-Smad4, ECFP-TIAF1 and/or a GFP-reporting plasmid with a SMAD-responsive element.
17,35 In controls, cells were
transfected with a negative or a positive plasmid. After 24h, the cells were imaged by ﬂuorescence microscopy. The extent of promoter activation was measured
(mean±S.D.; Student’s t-test; n¼3).
17,35 Smad4 induced the promoter activation, whereas TIAF1 suppressed the effect. Similar results were observed by tagging Smad4
or TIAF1 with DsRed (data not shown). neg, negativecontrol; pos, positivecontrol; null, electroporationwith medium only. (b) p53-deﬁcientNCI-H1299 cells were transfected
with DsRed-TIAF1, TIAF1dm or ECFP-WOX1, in the presence of the SMAD promoter plasmid. DsRed-TIAF1 induced spontaneous activation of the SMAD-governed
promoter,whereasthemonomericDsRedhadnoeffect.Arepresentativesetofpromoteractivationisshown(rightpanel).Bothnegativeandpositivecontrolswereincludedin
the experiments (mean±S.D.; Student’s t-test; n¼3)
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Cell Death and Diseaseand dnJNK1 caused apoptosis of control cells (Figure 6d).
TIAF1 or WOX1 knockdown cells resisted death caused by
the transiently overexpressed p53 and dnJNK1 (Figure 6d).
In contrast, when TIAF1 was knocked down in Mv1Lu cells,
apoptosis caused by transiently overexpressed Smad4 was
increased (subG1 phase; Figure 6e).
TIAF1, WOX1 and p53 synergistically induce apoptosis
and block anchorage-independent growth and cell
migration. We investigated whether TIAF1, WOX1 and
p53 act synergistically in causing apoptosis. L929 ﬁbroblasts
were grown on cover slips overnight, and co-transfected
with non-apoptosis-inducing amounts of p53, WOX1 and/or
TIAF1 plasmid constructs by the liposome-based Gene
Fector (Venn Nova, Pompano Beach, FL, USA). The cells
were then grown for 48h. When in combination, TIAF1, p53
and WOX1 dramatically induced apoptosis in a synergistic
manner (B75%) (Figure 7a). The combination of TIAF1/p53,
p53/WOX1 or TIAF1/WOX1 had a much less effect in
inducing apoptosis (0–25%) (Figure 7a). Similar results were
Figure 5 TIAF1 self-association induces expression of Smad4 and WOX1. (a) MCF7 cells were transiently transfected with ECFP and EYFP (C/Y) or ECFP-TIAF1 and
EYFP-TIAF1 (Tc/Ty) by liposome. The cells were treated with or without TGF-b1 (5ng/ml) for 24h. TIAF1 self-binding was analyzed by FRET microscopy.
11,17,35 FRETc
shows the extent of protein/protein binding.
11,17,35 TIAF1 self-binding led to Smad4 expression, as determined by immunoﬂuorescence staining. Statistical analysis: all tests
versus C/Y controls; Student’s t-test (n¼6). The induced Smad4 colocalized with TIAF1 in the cytoplasm and the spiny protrusion ( 400 magniﬁcation; Supplementary
FigureS10).(b)TransientlyoverexpressedEGFP-TIAF1upregulatestheexpressionofSmad4andWOX1inMCF7(non-reducingSDS-PAGE)andothertypesofcancercells
(data not shown). Exposure of cells to Prima-1 (10mM) for 1h to activate p53 resulted in increased polymerization of TIAF1 and WOX1, but not Smad4. (c) COS7 cells were
transiently overexpressed with EGFP-TIAF1 or EGFP. Signiﬁcantly increased expression of WOX1 is shown, where these proteins colocalize with TIAF1 aggregates, as
determined using speciﬁc antibodies (n¼10; mean±S.D.; experiments versus EGFP controls, Student’s t-test). Dominant-negative TIAF1 (E22/23A) and EGFP failed to
induce the indicated protein expression. (d) To stimulate endogenous TIAF1 aggregate formation, COS7 and/or SK-N-SH cells were co-cultured on the ECM of prostate
DU145 cells for48h. Aggregate formation of endogenous TIAF1, along with WOX1 expression, is shown in the cytoplasm of both cells (top two rows). No TIAF1 aggregate
formation was observed by culturing COS7 cells alone on the ECM (third row from the top). R48-2 blocking peptide abolished the immunoﬂuorescence (bottom row).
(e)NCI-H1299cellsweretransientlyoverexpressedwithECFP-Smad4andEYFP-TIAF1,followedbytreatingwithTGF-b1(5ng/ml)for24h.IncreasedbindingofSmad4and
TIAF1 positively correlates with upregulation of APP and Ab
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Cell Death and Diseasealso observed in COS7, NCI-H1299 and other cells (data not
shown).
When L929 cells were co-transfected with the above
constructs, followed by performing anchorage-independent
growth, TIAF1, p53 and WOX1 together dramatically sup-
pressed colony formation by 495% (Figure 7b). Each protein
alone blocked colony formation by B50%, and that two
proteins together increased the suppression up to 65–90%
(Figure 7b). We have previously shown that p53 and TIAF1
together effectively block the anchorage-independent growth
of L929 cells.
7
In parallel experiments, ectopic expression of p53, WOX1
and TIAF1 signiﬁcantly blocked the migration of L929 and
breast MDA-MB231 cells during the observation for 16h
(Figure 7c and Supplementary Figure11a). Non-apoptosis-
inducing levels of expression plasmids for p53, WOX1 and
TIAF1 were used in introducing into cells. The effect
was observed by testing each protein alone or in various
combinations. Interestingly, under similar conditions, ectopic
p53, WOX1 and TIAF1 in combination were less effective in
blocking the migration of breast MCF7 than those of p53 and
WOX1 alone (Supplementary Figure S11b).
Of particular note is that when normal cells such as
ﬁbroblasts and cardiomyocytes were expressed with p53,
WOX1 and TIAF1, these cells became highly sensitive to
deathinducedbycytokinesTNF-aandTGF-b1in4h(datanot
shown). Again, the observations suggest thatp53, WOX1 and
TIAF1 can act in concert to drive the cell death event.
Discussion
In summary, we have determined that (1) TIAF1, along with
Smad4 and Ab, participates in the formation of peritumor
capsules, which is crucial for solid tumor growth
and protection; (2) under the stimulation of non-self
ECM, endogenous TIAF1 is upregulated and undergoes
Figure 6 TIAF1 is essential for apoptosis mediated by WOX1, p53 and dominant-negative JNK1. (a) Mv1Lu cells were transfected with expression plasmid constructs of
WOX1 and/or TIAF1si by electroporation, followed by culturing for 48h. The extent of cell growth was measured by MTS proliferation assay. TIAF1 knockdown cells resisted
WOX1-inducedgrowthinhibition(n¼8;mean±S.D.;Student’st-test:experimentsversusscramblecontrols).Scram¼‘scrambledRNA’controlplasmid.(b)L929cellswere
transfected with WOX1 and/or TIAF1si plasmids, and then grown in soft agarose for 3 weeks to allow colony formation (measured by MTS proliferation assay) (n¼3;
Student’st-test;experimentsversusscramblecontrols).(c)WhenL929cellsweretransfectedwithWOX1andTIAF1plasmids(1.25mgper10
6cells),bothexpressedproteins
synergistically caused cell death (B40%, n¼8). Dominant-negative WOX1 (dnWOX1)
17 and phospho-WOX1 mutants (Y33R and Y61R)
17 failed to induce cell death, in the
absence or presence of TIAF1 (n¼8; Student’s t-test: experiments versus scramble controls). (d) L929 stable transfectants, expressing a scramble, TIAF1si or WOX1si
construct,wereestablished.Transientoverexpressionofthesecellswithanemptyvector,p53ordnJNK1constructwascarriedout,andtheextentofcelldeathwasmeasured
in48h(n¼8;Student’st-test;experimentsversusscramblecontrols).WhenTIAF1andWOX1wereknockeddown,ectopicp53anddnJNK1-inducedcelldeathwasblocked.
(e) In contrast, when TIAF1 was knocked down, Smad4-induced apoptosis of Mv1Lu cells was enhanced (see subG1 phase; a representative data from two experiments). a,
SubG1 phase; b, G0/G1 phase; c, S phase; d, G2/M phase
TIAF1 self-aggregation and cancer growth and death
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Cell Death and Diseaseaggregation, which binds Smad4 and blocks SMAD promoter
activation;
11 (3) however, in the absence of p53, the
aggregating TIAF1 activates the SMAD-governed promoter;
(4) increased levels of TIAF1 induces WOX1 expression, and
vice versa; (5) TIAF1 is essential in the p53- and WOX1-
mediated cell death, and these proteins act synergistically in
inducing cell death (Figure 8).
Alteration of TIAF1 levels appears to affect cancer
progression. We showed that UVB-induced SCC formation
in rats is associated with an initial upregulation of TIAF1,
followed by reduction in the cancer. This expression proﬁle
positively correlates the expression of WOX1 protein during
SCC development.
15 Also, TIAF1 is accumulated in develop-
ing metastatic tumor cells when growing in a new organ site.
Once the metastatic solid tumors become established, TIAF1
is signiﬁcantly downregulated. The observation suggests that
TIAF1 is central to cancer progression. TIAF1 may exhibit as
ﬁbrous aggregates, together with Smad4, Ab and other
proteins, in the stromal tissues of tumors and peritumor
capsules. Also, both TIAF1 and Smad4 are co-present in the
normal prostatic concretions in the lumens of prostatic
glandular ducts, and they are intracellular proteins. How
these proteins become secreted remains to be established.
Whether the extracellular TIAF1 and Smad4 are functionally
inactive is unknown.
A developing tumor circumvents pericellular and environ-
mental challenges. It is not surprising to see dramatic
upregulation or downregulation of critical proteins, either
intracellular or extracellular, in a single cancer cell during
division and continuous expansion.
21,22 For example, during
metastasis, cancer cells frequently have reduced expression
of tumor suppressors probably because of gene mutation or
epigenetic inactivation.
23,24 These cells may utilize strategies
by signiﬁcantly increasing the production of TGF-b, hyalur-
onan, hyaluronidases, metalloproteinases, gain-of-function
isoforms of tumor suppressors and others to facilitate
migration to target organs.
25-27 In contrast, at the benign
stage, physical protection is built surrounding the peritumor
area for allowing the growth and formation of a solid
tumor.
28,29
In our previous study, we have shown that TIAF1 aggrega-
tion in the hippocampus is essential for amyloid b deposition
and formation of ﬁbrils and plaques.
11 What leads to TIAF1
self-aggregationislargelyunknown.Wehavedeterminedthat
under the stress of cytokines or chemicals and/or alteration
of pericellular matrix, TIAF1 becomes self-associated or
aggregated.
11 In this study, we further demonstrated that
upon co-culturing of COS7 and SK-N-SH cells on the ECM of
Figure 7 TIAF1, WOX1 and p53 synergistically induce apoptosis, block cell
migration and inhibit anchorage-independent growth. (a) L929 cells were
co-transfected with non-apoptosis-inducing amounts of wild-type p53, WOX1 and/
or TIAF1 plasmid constructs (2.5mg) by the liposome-based GeneFector. The
extent of cell death was measured by nuclear morphology. Nuclei were stained with
DAPI(mean±S.D.;n¼8;Student’st-test).(b)L929cellsweretransfectedwiththe
above constructs by electroporation, and then subjected to performing anchorage-
independent growth assay. After 3 weeks, the live cell colonies were measured by
staining with the MTS proliferation assay (mean±S.D.; n¼8; Student’s t-test).
(c) Under similar conditions, L929 cells were transfected with non-apoptosis-
inducing amounts of wild-type p53, WOX1 and/or TIAF1 plasmid constructs. The
transiently overexpressed p53, WOX1 and TIAF1, alone or in combinations,
signiﬁcantly blocked the migration of L929 cells (mean±S.D.; n¼3; Student’s t-
test). P value is shown on the top of each bar. The number in each bracket is ‘fold
increase’ in cell migration
Figure 8 TIAF1 aggregation and associated events. (1) Under environmental
alterations (e.g., non-self ECM), endogenous TIAF1 is prone to aggregation, which
is critical for supporting peritumor capsule formation; (2) During self-aggregation,
TIAF1 binds Smad4 and blocks SMAD promoter activation; (3) Intriguingly,
under p53-deﬁcient conditions, aggregating TIAF1 supports the activation of the
SMAD-governed promoter; (4) Overexperssed TIAF1 induces WOX1 expression,
and vice versa; (5) TIAF1, p53 and WOX1 act synergistically in causing growth
suppression and cell death
TIAF1 self-aggregation and cancer growth and death
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Cell Death and Diseaseprostate DU145 cells, endogenous TIAF1 and WOX1 are
upregulated and become aggregated. The observations
support the scenario that an unfriendly environment induces
endogenous TIAF1 aggregation. TGF-b rapidly induces
TIAF1 self-aggregation, which leads to apoptosis in a
caspase-dependentmannerincertaincells.
11Overexpressed
TIAF1 affects Smad signaling and transcriptional activation.
TIAF1 binds Smad4 in vivo, and blocks Smad-dependent
promoter activation. Accordingly, when TIAF1 protein expres-
sionisknockeddownbysiRNA,spontaneousaccumulationof
Smad proteins in the nucleus occurs, along with activation
of the SMAD-regulated promoter.
11 Interestingly, TGF-b1
induces TIAF1 self-aggregation in a TbRII-independent
manner, and this may be related with binding of TGF-b1
to membrane hyaluronidase Hyal-2.
17 Indeed, TGF-b is able
to signal via a Smad-independent manner for activation of
NF-kB and JNK,
30 induction of lymphoid enhancer-binding
factor (Lef-1) transcription factor,
31 and terminal skeletal
muscle differentiation.
32
TIAF1 is a likely gatekeeper in regulating cancer progres-
sion. TIAF1 is upregulated during the early stage of SCC
formation. The developed SCC tumor has reduced TIAF1
expression. In prostate cancer, TIAF1 is most upregulated in
the cancerous stage, but is downregulated during cancer
metastasis. Interestingly, the expression proﬁle of tumor
suppressor WOX1 exhibits similarly to that of TIAF1 during
cancer progression in vivo.
15,33,34 That is, both WOX1 and
TIAF1 are signiﬁcantly upregulated during the early phases
of benign tumor formation. However, both proteins are
downregulated when tumors possess metastatic potential.
We determined that ectopic WOX1 induces the expression of
TIAF1. WOX1 is known to enhance the transcriptional
activation of SMAD and NF-kB promoters,
17,35 suggesting
that TIAF1 expression is controlled by both promoters. TIAF1
in turn induces the expression of Smad4 and Ab, depending
upon the status of TIAF1 self-aggregation. TIAF1/Ab aggre-
gates are ‘natural and protective fences’ for both cancer and
neural cells, but are likely to induce neurodegeneration during
long-term exposure.
TIAF1self-bindingisessentialforincreasingtheexpression
of Smad4 and WOX1. The underlying mechanism is
unknown. Interestingly, the induced Smad4 colocalizes with
TIAF1, and WOX1 appears to undergo self-association or
binding with other proteins. Smad4 is able to interrupt
the TIAF1 aggregation.
11 We have shown that when cells
possess a greater amount of TIAF1 than Smad4, these
cells survive upon challenge with TGF-b1. However, when
cells express a greater amount of Smad4 than TIAF1, they
were highly sensitive to TGF-b1-induced apoptosis.
11 In this
study, we have conﬁrmed the observations by TIAF1 knock-
down and shown increases in Smad4-mediated apoptosis.
Thus, a dynamic balance between Smad4 and TIAF1 is
critical for cell survival.
We provided supporting evidence that TIAF1 is essential in
the p53, WOX1 and dnJNK1-mediated cell death. And, these
proteins can act synergistically in inducing cell death. How
TIAF1 has such crucial effects is unknown. Conceivably, a
direct interaction between TIAF1 and WOX1 occurs, which
further connects the binding with p53. This scenario needs
further study.
Materials and Methods
Cell lines, prostate cancer tissue microarrays, cancer tissue
sections, IHC, antibodies and synthetic peptides. Cell lines used in
the study were monkey kidney COS7 ﬁbroblasts, murine L929 ﬁbroblasts, mink
lung Mv1Lu cells, human breast MCF7 and MDA-MB-231 cells, human lung NCI-
H1299 cells, human neuroblastoma SK-N-SH cells and human prostate DU145
cells (American Type Culture Collections, Manassas, VA, USA). Puriﬁed human
platelet-derived TGF-b1 and recombinant TGF-b1 were purchased from R&D
Systems (Minneapolis, MN, USA) and PeproTech (Rocky Hill, NJ, USA),
respectively. Prostate cancer tissue microarray slides (T-RP-2D), containing 75
samples each for control and cancer groups, respectively, were obtained from the
Tissue Array Research Program, National Cancer Institute (Bethesda, MD, USA).
In addition, human cancer tissue sections were obtained from the Department of
Pathology, University of Colorado Health Sciences Center (by Dr. CI Sze, before
2005). IRB approval was waived. Informed consents were obtained from the family
members of the deceased patients. Also, cancer tissue sections were obtained
from the MacKay Memorial Hospital, Taipei, Taiwan (by Dr. MF Chiang) with IRB
approval. De-paraﬁnization, IHC and immunoﬂuorescence staining were
performed as described.
11,36 Presence of autoﬂuorescence in each tissue section
was examined by ﬂuorescence microscopy. In most cases, we pre-blocked the
autoﬂuorescence of tissues by Sudan Black B (Sigma, St. Louis, MO, USA) before
immunostaining.
37
SpeciﬁchomemadeantibodieswereagainstTIAF1(R48-2)
5,11andWOX1.
12,17,38
The sequence of R48-2 peptide is NH-AAGDAGEESRVQVLKNEVRR-COOH
(amino acid #16–35; Genemed Synthesis, San Antonio, TX, USA). The TIAF1
(R48-2) antibody was used mainly for IHC and ﬂuorescent immunostaining. Where
indicated, this peptide (20mM) was used to absorb the produced TIAF1(R48-2)
antibody (1ml) in negative control experiments for IHC and ﬂuorescent
immunostaining.
36 Also, we generated antibody TIAF1-R48-1 (amino acid
#44–60; NH-VEQAYVDKCVCGPSA-COOH) in rabbits, as described.
12 The
following speciﬁc antibodies used were against: Ab (MCA2172, AbD/Serotec,
Kidlington, UK),
11 APP (MAB348, Chemicon/Millipore, Temecula, CA, USA),
11
Smad4
11 (Santa Cruz Laboratory, Santa Cruz, CA, USA), a tubulin (Sigma) and
TIAF1 (Abcam).
11 Fluoro-Jade C (Millipore, Billerica, MA, USA) was used to stain
degenerating neurons. Adobe Photoshop CS5 software was used to analyze the
extent of protein expression from western blots.
cDNA expression constructs and FRET. TIAF1si, scrambled RNA and
stable L929 cell transfectants were prepared as previously described.
5,7 TIAF1
and Smad4 were tagged with enhanced green ﬂuorescence protein (EGFP; in
pEGFP-C1, Clontech, Mountain View, CA, USA), ECFP in pECFP-C1 (Clontech)
or DsRed in pDsRed (Clontech).
5,7,17 These are mammalian expression plasmids.
Additional mammalian expression plasmids were WOX1, p53, dominant-negative
TIAF1 (E22/23A), dnJNK1 and dnWOX1.
7,12,17 Where indicated, L929, MCF7,
NCI-H1299 cells or other indicated cells were electroporated with the above
constructs (200V, 50msec; Square Wave BTX ECM830, Genetronics, San Diego,
CA, USA), cultured overnight and then treated with TGF-b1 for indicated times.
Alternatively, the cells were transfected with the aforementioned DNA constructs
using liposome-based Genefector (Venn Nova). Whole cell lysates were prepared
in the presence of a cocktail of protease inhibitors (Sigma). The extent of protein
expression was determined using indicated speciﬁc antibodies in each indicated
experiment. FRET analysis for bimolecular interactions was carried out as
described.
11,17,35 Brieﬂy, cells were stimulated with an excitation wavelength of
440nm. FRET signals were detected at an emission wavelength of 535nm. ECFP
and EYFP were used as donor and acceptor ﬂuorescent molecules, respectively.
The FRET images were corrected for background ﬂuorescence from an area free
of cells. The spectrally corrected FRET concentration (FRETc) was calculated
using a software program (Image-Pro Plus 6.1, Media Cybernetics, Bethesda, MD,
USA) using Youvan’s equation:
FRETc¼ fretbk fret ½  ðÞ   cf don ½    ð don bk don ½  Þ   cf acc ½    ð acc bk acc ½  Þ ;
where fret¼fret image, bk¼background, cf¼correction factor, don¼donor
image and acc¼acceptor image. The equation normalizes the FRET signals to
the expression levels of the ﬂuorescent proteins.
Quantiﬁcation of ﬂuorescent images. Fluorescent or immunoﬂuores-
cent microscopy was performed using a NIKON TE2000-U microscope (Nikon,
Tokyo, Japan), as described.
11,17,35,39 For prostate cancer tissue microarray
slides, the relative extent of protein expression in each section was quantiﬁed
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Each slide was quantiﬁed independently by two laboratory researchers.
For cultured cell images, the relative ﬂuorescence intensities of whole cells or
individual punctates were quantiﬁed by Photoshop (under the Histogram and
Marquee or Quick Selection tools, Adobe Photoshop CS5) and by Nikon’s
software. For each control or experiment, 20–100 cells were examined in
3–5 experiments. Presented data were from analyses by Photoshop.
Cell proliferation assay and ﬂow cytometry. MTS tetrazolium assay
(CellTiter 96 AQueous OneSolution Cell Proliferation Assay, Promega, Madison,
WI, USA) was used to measure the extent of cell and colony growth.
7 In addition,
cells were transfected with the TIAF1 or indicated constructs by electroporation
and cultured for 24–48 h, followed by determining the extent of apoptosis and
growth suppression by cell cycle analysis using a ﬂuorescence-activated cell
sorting/ﬂow cytometry machine (BD, Sparks, MD, USA), as described.
7,39
UVB irradiation on hairless mouse skin. The in vivo experiments were
performed, as described.
15 An approved protocol for animal use was obtained
from the Institutional Animal Care and Use Committee of the National Cheng Kung
University Medical College. Brieﬂy, hairless SKH-hr1 female mice, 6-week-old,
were obtained from Charles River Laboratories (Wilmington, MA, USA). The mice
were housed in individual cages in a room with a constant temperature and
humidity and an alternating 12-h light and dark cycle, and fed ad libitum with a
commercial diet and water. To examine acute response, three mice were exposed
to UVB (2.16kJ/m
2; 312nm) once using a BLE-8T312 UV lamp (Spectronics,
Westbury, NY, USA), and the mice were killed 1 day later. To determine chronic
response, mice were exposed to UVB thrice per week (Monday, Wednesday and
Friday) starting with 0.36kJ/m
2, respectively, for 1 and 5 months (n¼3), followed
by increasing 100% weekly. After week 10, a consistent dose of UVB irradiation
(2.16kJ/m
2) was given over the next 8 weeks. In a control group, mice received no
UVB irradiation. Skin tissue sections were prepared
15 and processed for IHC
staining using TIAF1(R48-2) antibody.
Cell migration or wound healing assay. Cell lines, including breast
MDA-MB-231 and MCF cells and murine L929 ﬁbroblasts, were transiently
transfected with expression constructs for p53, TIAF1 and/or WOX1 cDNA by
electroporation.
5,12,17 Cell migration assay was performed by using Culture-Inserts
(ibidi, Verona, WI, USA) in the petridishes, as described.
40 A culture insert was
placed on a 35-mm dish, and an equal number of cells (2.8 10
4 cells in 70ml
RPMI or DMEM medium) were seeded into the two reservoirs of the same insert,
so as to generate a 500±50mM gap between two cell populations. After 24-h
incubation at 371C with 5% CO2, the insert was gently removed and the medium
was removed. Migration experiments were then conducted under serum-free
medium. The extent of cell migration was imaged for indicated times using the
NIKON TE2000-U microscope.
17,39
Data analysis. All experiments indicated above were performed 2–5 times.
Data were presented as mean±S.D. Student’s t-tests were performed
for statistical analysis where indicated.
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